Abstract Number: 1L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Background/Purpose: Sprifermin, a novel recombinant human fibroblast growth factor-18 is currently investigated as a potential disease-modifying osteoarthritis (OA) drug. Two-year primary data from a 5-year…Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
*Both authors (Husni, Solomon) contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…
Search by Abstract Number Results
Didn't find what you were looking for? Try the Advanced Search »